Speaker Profile

Ph.D., Founder, Chairman & CEO, AccurEdit Tx

Biography
Previously CEO of CMAB BioPharma, President of Pharmaceuticals of Simcere Pharmaceutical Group, CEO of Kanghong Biotech, and Staff Scientist at Genzyme Corporation. Led CMAB to become the fastest growing biopharmaceutical CDMO company in China, later acquired by WuXi Biologics in 2021.Managed a global team of more than 1,700 people and multiple commercialized companies at Simcere (publicly listed in HKEX).At Kanghong Biotech (publicly listed in China), first as head of CMC and quality and later as CEO, developed and marketed Conbercept, the first innovative biological drug with an INN to reach 1 billion RMB revenue in China and the first approved by the FDA to directly enter clinical phase III in 2016. At Genzyme responsible for the post-market maintenance of the first and second cell therapies approved by the FDA and the development of key CMC projects for the first FDA-approved tissue engineering product. Publications cited over 4,000 times.


Talk
Potentially BIC Gene Editing Product for ATTR
Our clinical data indicated that AccurEdits leading pipeline product (ART001) has the potential to be the best-in-class in vivo gene editing product for ATTR with 90% serum TTR reduction after 4 weeks, no off-target editing or DNA translocation at up to 80 times EC90, and no infusion-related reactions.


Emerging Therapeutics Showcase:
AccurEdit Therapeuti

AccurEdit Therapeutics has established an end-to-end in vivo gene editing platform and has become the first and only company to demonstrate safe and effective systemic CRISPR gene editing in humans in China.

 Session Abstract – PMWC 2024 Silicon Valley

Showcase Track S1 - January 25 9.30 A.M.-4.30 P.M.,Showcase Track S1 - January 26 10.00 A.M.-10.30 A.M.


The PMWC 2024 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.

  • Emerging Therapeutics/Cell Therapy
  • Emerging Therapeutics/CVD
  • Emerging Therapeutics/Gene Therapy
  • Emerging Therapeutics/Immunotherapy
  • Emerging Therapeutics/Radiation Therapy

×

Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by AUG. 1ST

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required